Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2008

Filing Date
Filed February 20, 2009
Period End
December 31, 2008
Security
IDXX
One revenue dollarkept$0.11
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 20, 2009. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' fiscal 2008 10-K shows a company that grew revenue 11% to $1.024 billiona and expanded operating income 27% to $172.5 million, with net income up 24% to $116.2 million and diluted EPS of $1.87 (up from $1.46).

Growth was led by the Companion Animal Group (CAG), which rose 11% to $834 millionb on higher instrument and consumable sales, the launch of the Catalyst Dx and SNAPshot Dx analyzers, and strong rapid assay and reference laboratory volumes. Gross margin improved to 51.7% from 50.2%, though management flagged near-term pressure from higher instrument placements as Catalyst Dx penetrates the base. Investors should weigh several headwinds for 2009: the loss of Cryptosporidium testing revenue in England and Wales (Filta-Max sales of $2.8 million), a roughly 30% reduction in the EU's BSE testing population affecting the Production Animal Segment, expiration of the FIV patent in June 2009 that will pressure SNAP FIV/FeLV margins, and the wind-down of the veterinary pharmaceutical business after the Q4 2008 sale.

Balance sheet leverage rose: total debt climbed to $156.5 millionc from $78.7 million, largely to fund share repurchases ($132.3 million in 2008) and the Westbrook, Maine facility expansion. Cash flow from operations was $143.3 million, and the company disclosed no material exposure from the Cyntegra antitrust suit, which was dismissed at the trial level and is on appeal. Overall, the filing portrays a financially healthy, growing company with strong margins and heavy capital return, but with visible 2009 revenue headwinds from regulatory and patent changes and a notable dependence on a single distributor (Butler Animal Health Supply, 8% of revenue) and on sole-source suppliers such as Ortho for chemistry slides.

Key Highlights

  1. Revenue rose 11% to $1,024.0 million, with Companion Animal Group up 11% to $834.1 million and Water up 12% to $74.5 million.
  2. Operating income increased 27% to $172.5 million, and operating margin expanded to 16.8% from 14.8%.
  3. Diluted EPS grew 28% to $1.87, aided by a reduced share count after heavy buybacks (diluted shares down to 62.2 million from 64.5 million).
  4. Total debt more than doubled to $156.5 million under the $200 million revolving Credit Facility, which funded repurchases of $132.3 million and facility expansion; no dividends are paid.
  5. Known 2009 headwinds include loss of Filta-Max sales in England and Wales ($2.8 million), a roughly 30% smaller EU BSE testing population, and the June 2009 expiration of the FIV patent covering SNAP FIV/FeLV tests.
  6. The veterinary pharmaceutical business was sold or restructured in Q4 2008, so pharmaceutical product revenue ($19.1 million in 2008) is expected to be essentially eliminated in 2009.
  7. International sales represent 40% of revenue, and a 10% stronger U.S. dollar would reduce operating income by about $7.2 million in 2009.

Follow one dollar

Of each $1.00 of revenue in FY2008, IDEXX Laboratories kept $0.11.

  1. Revenue$1.02B100.0%
  2. Cost of revenue−$494.3M48.3%
  3. Gross profit$529.8M51.7%
  4. Operating costs−$357.3M34.9%
  5. Operating income$172.5M16.8%
  6. Interest, other & tax−$56.3M5.5%
  7. Net income$116.2M11.3%
Computed from 10-KFY2008filed February 20, 2009Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2008 revenue went

$1.02B
  • Cost of revenue: $494.3M, 48% of revenue
  • Other operating costs: $286.6M, 28% of revenue
  • Net income: $116.2M, 11% of revenue
  • R&D: $70.7M, 6.9% of revenue
  • Interest, other & tax: $56.3M, 5.5% of revenue

Kept 11% as net income

Full revenue history →

Frequently Asked Questions

  1. What drove IDEXX's revenue growth in 2008?

    Growth came mainly from the Companion Animal Group, where instruments and consumables rose 10%, laboratory and consulting services rose 13%, and rapid assay sales rose 10%. Drivers included the Catalyst Dx and SNAPshot Dx analyzer launches, higher pricing on canine combination tests, and acquisitions contributing about 1% of total growth. Currency added roughly 1%. Growth was partly offset by lower VetTest instrument sales and a 2007 pet food recall that temporarily boosted prior-year testing volume.

  2. Why is the balance sheet more leveraged than in prior years?

    Short-term debt on the revolving Credit Facility increased to $150.6 million from $72.2 million, and total debt reached $156.5 million, compared with $78.7 million in 2007. The company borrowed to fund $132.3 million of share repurchases and ongoing construction of its Westbrook, Maine headquarters, which has about $35 million of projected spending through 2011. Management states the debt-to-EBITDA ratio is under 1-to-1 against a 3-to-1 covenant, and that existing cash, operating cash flow, and facility availability are sufficient for the foreseeable future.

  3. What are the biggest risks to 2009 results?

    The main risks include the loss of Cryptosporidium testing in England and Wales, which removes Filta-Max sales, and a reduced BSE testing population in the EU, which will lower sales of the post-mortem BSE test. The FIV patent expires in June 2009, which is expected to reduce revenue and margins for SNAP FIV/FeLV products. Macroeconomic weakness could reduce pet visits and diagnostic testing, and distributor purchasing patterns (such as Butler Animal Health at 8% of revenue) can create volatility. Reliance on sole-source suppliers, including Ortho for chemistry slides, is also a risk.

  4. Is the Cyntegra antitrust lawsuit a material concern?

    Cyntegra alleged monopolization of the U.S. companion animal diagnostics market. The trial court granted summary judgment in IDEXX's favor in October 2007 and dismissed the suit, and Cyntegra has appealed to the Ninth Circuit, with a hearing expected in mid-2009. Management believes the claims are without merit and states that other legal matters are not expected to have a material adverse effect. The filing does not quantify any potential exposure.

  5. How did margins and cash generation trend in 2008?

    Gross margin improved to 51.7% from 50.2%, mainly from higher sales volume, favorable currency effects, lower slide costs, and higher rapid assay pricing, partly offset by lower-margin instrument and laboratory mix. Operating cash flow was $143.3 million, up from $135.1 million, although working capital absorbed cash due to lower accounts payable and accrued expenses and higher instrument inventory for the Catalyst Dx and SNAPshot Dx launches. Capital expenditures were $89.2 million, leaving free cash flow of roughly $54 million before share repurchases.